Novo Nordisk A S (NVO) stock
NVONYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NONOF
Financials through fiscal 2025, year ended Dec 31, 2025Score 4/30
$39.43−1.27 (-3.12%)
Close on Nov 18, 2026Market cap $176.06BP/E 11.6Yield –
Novo Nordisk A S pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Novo Nordisk A S's pe ratio was 12.0× on Nov 11, 2026, against 14.0× a year earlier. Over the last 5 years it ranged from 10.3× to 67.3×, with a median of 38.2×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 12.0× | −2.4 |
| 2025 | Dec 31, 2025 | 14.3× | −19.0 |
| 2024 | Dec 31, 2024 | 33.3× | −23.8 |
| 2023 | Dec 29, 2023 | 57.0× | +11.7 |
| 2022 | Dec 30, 2022 | 45.4× | +4.5 |
| 2021 | Dec 31, 2021 | 40.9× | +14.9 |
| 2020 | Dec 31, 2020 | 25.9× | +1.8 |
| 2019 | Dec 31, 2019 | 24.2× | +4.7 |
| 2018 | Dec 31, 2018 | 19.5× | −2.7 |
| 2017 | Dec 29, 2017 | 22.2× | +3.5 |
| 2016 | Dec 30, 2016 | 18.7× | – |
See a number that looks wrong?